Will Hims & Hers Health stock hold above its 200-day moving average amid weak momentum?

Traders Union
All News
Stocks
Hims & Hers Health drops 6.78% today

Highlights

Securities class action lawsuits were filed against Hims & Hers Health and executives after the FTC alleged misleading disclosures and improper health data practices.
Shares of Hims & Hers Health dropped sharply on July 29, 2026, after the FTC legal action increased regulatory and legal risks.
Technical signals are decisively bearish with pronounced selling pressure, an expected four-day price range of $25.84 to $29.6, and a very high likelihood of further downside.

Regulatory and legal pressures intensify as lawsuits follow FTC action

Multiple securities class action lawsuits were filed against Hims & Hers Health and certain executives after the Federal Trade Commission (FTC) initiated legal action alleging misleading disclosures, pre-consultation prescription charges, and improper handling of health data with third-party advertisers, according to Globenewswire. News of the FTC complaint prompted a sharp share price drop on July 29, 2026, as reported by Prnewswire, reflecting investor reaction to heightened regulatory and legal risks. Separately, the company launched its Hers women's health platform in Australia through the rebranding of the acquired Eucalyptus venture Juniper, targeting expanded telehealth services for women, as covered by Ibtimes Com.

Persistent bearish momentum as oversold signals accompany resistance

On the H1 chart, HIMS is trading below the MA-20 at $29.56 and MA-50 at $29.4, both indicating short- and medium-term resistance. The price remains above the MA-200 at $27.32, while the Ichimoku Kijun at $29.69 acts as immediate resistance. Momentum indicators show a prevailing bearish bias: MACD and ADX are both negative, and the RSI, Stochastic RSI, and CCI all register in oversold territory, highlighting sustained downward momentum. Intraday, Bull/Bear Power points to persistent seller dominance, and the Awesome Oscillator corroborates this bearish trend.

Limited upside prospect as volatility band contains price action

In the near term, HIMS is likely to trade within a volatility band between $25.84 and $29.6 over the next four trading days. The probability of an upward scenario remains very low given current technical and momentum conditions. A bullish outcome would require a breakout above the key resistance at $29.69, while a breakdown below $25.84 would likely accelerate further declines. Consolidation within the defined corridor is the baseline scenario barring a decisive move beyond these technical thresholds.

Anton Kharitonov, expert at Traders Union, sees persistent downside risks for Hims & Hers Health in both technical and fundamental terms. He notes that ongoing regulatory challenges, class action lawsuits, and a sharp negative news-driven price reaction are weighing heavily on sentiment. With technicals deep in bearish territory and no strong reversal signal, he remains cautious about any short-term rebound. "Unless HIMS can reclaim resistance at $29.69 and resolve major legal overhangs, I see little justification for a bullish stance here."

Earlier, analysts noted that women’s health companies like Maven have pursued aggressive AI strategies to reduce costs and address data gaps, while the sector grapples with proving clear financial returns from these investments. The latest developments at Hims & Hers Health add regulatory scrutiny and legal uncertainties to the mix, making the $25.84 level a critical downside risk to monitor for traders awaiting resolution of both technical and fundamental challenges.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.